These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 15115804

  • 1. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
    Zorrilla EP, Reinhardt LE, Valdez GR, Inoue K, Rivier JE, Vale WW, Koob GF.
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804
    [Abstract] [Full Text] [Related]

  • 2. Effects of urocortin 2 and 3 on motor activity and food intake in rats.
    Ohata H, Shibasaki T.
    Peptides; 2004 Oct; 25(10):1703-9. PubMed ID: 15476937
    [Abstract] [Full Text] [Related]

  • 3. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
    Kageyama K, Kimura R, Suga S, Ogawa Y, Suda T, Wakui M.
    Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
    [Abstract] [Full Text] [Related]

  • 4. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE.
    Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
    [Abstract] [Full Text] [Related]

  • 5. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.
    Hashimoto K, Nishiyama M, Tanaka Y, Noguchi T, Asaba K, Hossein PN, Nishioka T, Makino S.
    Peptides; 2004 Oct; 25(10):1711-21. PubMed ID: 15476938
    [Abstract] [Full Text] [Related]

  • 6. Endogenous expression and in vitro study of CRF-related peptides and CRF receptors in the rat gastric antrum.
    Porcher C, Peinnequin A, Pellissier S, Meregnani J, Sinniger V, Canini F, Bonaz B.
    Peptides; 2006 Jun; 27(6):1464-75. PubMed ID: 16337313
    [Abstract] [Full Text] [Related]

  • 7. Human urocortin II, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat.
    Inoue K, Valdez GR, Reyes TM, Reinhardt LE, Tabarin A, Rivier J, Vale WW, Sawchenko PE, Koob GF, Zorrilla EP.
    J Pharmacol Exp Ther; 2003 Apr; 305(1):385-93. PubMed ID: 12649393
    [Abstract] [Full Text] [Related]

  • 8. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.
    Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
    [Abstract] [Full Text] [Related]

  • 9. Urocortins and the regulation of gastrointestinal motor function and visceral pain.
    Martinez V, Wang L, Million M, Rivier J, Taché Y.
    Peptides; 2004 Oct; 25(10):1733-44. PubMed ID: 15476940
    [Abstract] [Full Text] [Related]

  • 10. Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons.
    Staub DR, Evans AK, Lowry CA.
    Brain Res; 2006 Jan 27; 1070(1):77-89. PubMed ID: 16403469
    [Abstract] [Full Text] [Related]

  • 11. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
    de Groote L, Peñalva RG, Flachskamm C, Reul JM, Linthorst AC.
    J Neurochem; 2005 Jul 27; 94(1):45-56. PubMed ID: 15953348
    [Abstract] [Full Text] [Related]

  • 12. Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.
    Fekete EM, Inoue K, Zhao Y, Rivier JE, Vale WW, Szücs A, Koob GF, Zorrilla EP.
    Neuropsychopharmacology; 2007 May 27; 32(5):1052-68. PubMed ID: 17019404
    [Abstract] [Full Text] [Related]

  • 13. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2.
    Tsatsanis C, Androulidaki A, Dermitzaki E, Gravanis A, Margioris AN.
    J Cell Physiol; 2007 Mar 27; 210(3):774-83. PubMed ID: 17117478
    [Abstract] [Full Text] [Related]

  • 14. Expression and effects of metabotropic CRF1 and CRF2 receptors in rat small intestine.
    Porcher C, Juhem A, Peinnequin A, Sinniger V, Bonaz B.
    Am J Physiol Gastrointest Liver Physiol; 2005 May 27; 288(5):G1091-103. PubMed ID: 15637181
    [Abstract] [Full Text] [Related]

  • 15. Corticotropin-releasing factor, urocortin 1, and their receptors in the mouse spinal cord.
    Korosi A, Kozicz T, Richter J, Veening JG, Olivier B, Roubos EW.
    J Comp Neurol; 2007 Jun 20; 502(6):973-89. PubMed ID: 17444496
    [Abstract] [Full Text] [Related]

  • 16. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
    Okada R, Miller MF, Yamamoto K, De Groef B, Denver RJ, Kikuyama S.
    Gen Comp Endocrinol; 2007 Feb 20; 150(3):437-44. PubMed ID: 17188689
    [Abstract] [Full Text] [Related]

  • 17. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat.
    Spina MG, Merlo-Pich E, Akwa Y, Balducci C, Basso AM, Zorrilla EP, Britton KT, Rivier J, Vale WW, Koob GF.
    Psychopharmacology (Berl); 2002 Mar 20; 160(2):113-21. PubMed ID: 11875628
    [Abstract] [Full Text] [Related]

  • 18. Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner.
    Dermitzaki E, Tsatsanis C, Minas V, Chatzaki E, Charalampopoulos I, Venihaki M, Androulidaki A, Lambropoulou M, Spiess J, Michalodimitrakis E, Gravanis A, Margioris AN.
    Endocrinology; 2007 Apr 20; 148(4):1524-38. PubMed ID: 17194738
    [Abstract] [Full Text] [Related]

  • 19. Divergent role for CRF1 and CRF2 receptors in the modulation of visceral pain.
    Nijsen M, Ongenae N, Meulemans A, Coulie B.
    Neurogastroenterol Motil; 2005 Jun 20; 17(3):423-32. PubMed ID: 15916630
    [Abstract] [Full Text] [Related]

  • 20. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
    Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW.
    J Pharmacol Exp Ther; 1999 Feb 20; 288(2):729-34. PubMed ID: 9918582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.